In mice with a genetic form of kidney disease, taking a drug called fenofibrate seems to slow down the growth of kidney cysts and reduce harmful inflammation in the kidneys.

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Randomized Controlled Trial

Animal

2018 Jan 1

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Score: 12

DOI: 10.1152/ajprenal.00352.2017

Similar Assertions

Fenofibrate seems to slow down kidney disease in mice with a condition similar to polycystic kidney disease, making their kidneys healthier after five months of treatment.

87%

Fenofibrate, a drug that changes how the liver processes energy, seems to help reduce liver cysts and damage in a type of mouse with a genetic liver disease.

80%

In mice with a kidney disease similar to one in humans, giving them a drug called fenofibrate seems to boost the activity of genes that help burn fat for energy in the kidneys, which might mean their kidney cells are using energy more efficiently.

72%